Hengsai Bio Completes First Strategic Financing Round to Advance DC Vaccine Pipeline and Global Strategy

On December 30, 2025, Hengsai Biotech announced the completion of its first round of strategic financing, with Tasly Capital as the investor. The proceeds will mainly be used to accelerate the research and development and clinical trials of the company’s core cell drug pipelines, and to support the company’s international strategic layout.

Since its establishment in November 2018, Hengsai Biotech has been focusing on the research and industrialization of dendritic cell (DC) vaccines. Relying on its self-developed Eco-DC Vax technology platform, the company has achieved a series of breakthroughs in the safety, therapeutic effects, and large-scale production processes of tumor vaccines. The company’s first investigational cell drug, KSD-101, is not only the world's first broad-spectrum DC vaccine targeting the Epstein-Barr virus (EBV), but also China’s first original DC vaccine to receive FDA IND approval.

DC Vaccine: A Dendritic Cell-Based Immunotherapy Drug

At this year's European Hematology Association (EHA) Congress, Hengsai Biotech showcasedKSD-101Positive Clinical Outcomes in Various EBV-Associated Lymphoproliferative Disorders (EBV-LPDs). Results from the ongoing Phase I clinical trial indicate that the drug demonstrates favorable safety and efficacy in multiple refractory conditions, including Angioimmunoblastic T-cell Lymphoma, NK/T-cell Lymphoma, and Chronic Active EBV Infection. Treatment-related adverse effects were mostly mild, with no ≥Grade 3 severe toxicity observed, showing good tolerability. The recommended Phase II clinical dose has been established as 5×10⁶ DCs/dose. At a median follow-up of 42.7 weeks, most patients achieved and maintained complete remission (CR), with preliminary efficacy data being highly encouraging. Leveraging its technological advantages such as multi-antigen presentation, overcoming HLA restrictions, and synergistic activation of CD4⁺ and CD8⁺ T cells, KSD-101 not only brings new hope for the treatment of EBV-associated tumors but also lays a solid foundation for future expansion into virus-related cancers such as HPV, HBV, and KSHV, highlighting China's innovative strength in the field of tumor immunocellular therapy.

In August this year, Hengsai Bio's Lingang R&D and production base was launched. This large-scale cell drug production base has a total investment of approximately 700 million yuan, covering an area of over 6,300 square meters. Equipped with internationally advanced professional facilities, it has the capacity to produce dendritic cell (DC) vaccines for 5,000 patients annually, with an expected annual output value of about 1.5 billion yuan. The official launch of this base marks the company's successful establishment of a complete chain from basic research to large-scale industrialization. Not only does it represent a significant leap in the company’s own development, but it also effectively fills the gap in China’s DC vaccine industrialization field, opening up new treatment hopes for patients in areas such as relapsed and refractory tumors, chronic viral infections, and autoimmune diseases.

E.N.D

ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe team of the WeChat Official Account "Cell and Gene Therapy Field" has established a professional communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following information when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also indicate.